<DOC>
	<DOCNO>NCT00312520</DOCNO>
	<brief_summary>The purpose study determine pulse steroid efficacious safer standard treatment oral corticosteroid .</brief_summary>
	<brief_title>Pulse Steroids Versus Oral Steroids Problematic Hemangiomas Infancy</brief_title>
	<detailed_description>Currently prospective study hemangioma patient answer critical question : type steroid use , much use long . This study investigator blind study two arm : one arm receive standard treatment daily oral corticosteroid receive intravenous pulse corticosteroid daily 3 day , monthly 3 month . The main outcome study assess efficacy treament modality percentage improvement hemangioma 's appearance . The secondary outcome safety profile two drug change angiogenesis marker result treatment intervention .</detailed_description>
	<mesh_term>Hemangioma</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>problematic facial hemangioma ( periorbital/facial hemangioma potential visual obstruction , large/dysfiguring hemangioma ) 14 month age sign consent form refusal participate age &gt; 4 month complicate nonvisible hemangioma congenital heart disease</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>4 Months</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>